If I'm not mistaken this Ph1 trial should give us some strong efficacy signals too? I believe the main aim was to ensure no adverse reaction when combining the constituent substances making up IHL-675A.
Should be the start of unlocking another significant market if successful. I know focus has been on OSA but isn't the market potential for IHL-675A actually larger?
